Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
Brandon Folkes

Brandon Folkes Analyst Performance

Analyst at HC Wainwright

Brandon Folkes is a stock analyst at HC Wainwright in the healthcare sector, covering 38 publicly traded companies. Over the past year, Brandon Folkes has issued 82 stock ratings, including buy, hold, and sell recommendations. While full access to Brandon Folkes' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Brandon Folkes' coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
174 Last 10 Years
Buy Recommendations
93.64% 162 Buy Ratings
Companies Covered
38 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.6%1 ratings
Buy93.1%161 ratings
Hold5.8%10 ratings
Sell0.6%1 ratings

Out of 173 total stock ratings issued by Brandon Folkes at HC Wainwright, the majority (93.1%) have been Buy recommendations, followed by 5.8% Hold, 0.6% Strong Buy, and 0.6% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
84.2% of companies on NASDAQ
32 companies
NYSEAMERICAN
5.3% of companies on NYSEAMERICAN
2 companies
NYSE
5.3% of companies on NYSE
2 companies
TSE
2.6% of companies on TSE
1 company
OTCMKTS
2.6% of companies on OTCMKTS
1 company

Brandon Folkes, an analyst at HC Wainwright, currently covers 38 companies listed on NASDAQ, NYSEAMERICAN, NYSE, TSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
38 companies
100.0%

Brandon Folkes of HC Wainwright specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
PHARMACEUTICALS
22 companies
57.9%
BIOTECHNOLOGY
12 companies
31.6%
HEALTHCARE EQUIPMENT & SUPPLIES
4 companies
10.5%

About Brandon Folkes

Brandon Folkes has over a decade of experience in biopharma and biotechnology equity research. Prior to joining H.C. Wainwright, he served as Managing Director, Equity Research at Rodman & Renshaw and Managing Director, Equity Research at Cantor Fitzgerald. Prior to his tenure at Cantor, Mr. Folkes held equity research positions at Guggenheim Partners and CRT Capital. Before joining Wall Street, Mr. Folkes occupied roles at KPMG and PwC in the U.S., South Africa, and British Virgin Islands. Mr. Folkes holds degrees from Stellenbosch University and The University of South Africa; and earned the CFA and Chartered Accountancy designations.
Follow on LinkedIn

Brandon Folkes' Ratings History at HC Wainwright

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
10/23/2026Reiterated Rating$6.50Buy
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
10/8/2026Reiterated Rating$0.94Buy
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
10/6/2026Reiterated Rating$0.77Buy
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
10/5/2026Reiterated Rating$9.14$29.00Buy
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
10/2/2026Reiterated Rating$0.98Buy
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
10/1/2026Reiterated Rating$9.10$11.00Buy
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
9/28/2026Reiterated Rating$9.24$29.00Buy
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
9/23/2026Reiterated Rating$12.42$20.00Buy
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
9/23/2026Reiterated Rating$1.88$9.00Buy
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
9/14/2026Reiterated Rating$1.71$7.00Buy
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
9/3/2026Reiterated Rating$1.23Buy
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
8/25/2026Reiterated Rating$10.29$29.00Buy
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
8/21/2026Reiterated Rating$0.85Buy
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
8/20/2026Reiterated Rating$12.13$26.00Buy
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
8/18/2026Reiterated Rating$0.84Buy
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
8/18/2026Reiterated Rating$0.54$1.00Neutral
Talphera, Inc. stock logo
TLPH
Talphera
8/13/2026Reiterated Rating$1.40$3.00Buy
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
8/12/2026Reiterated Rating$6.77$12.00Buy
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
8/11/2026Downgrade$0.34Neutral
Omeros Corporation stock logo
OMER
Omeros
7/27/2026Reiterated Rating$10.78Buy
MannKind Corporation stock logo
MNKD
MannKind
7/23/2026Reiterated Rating$3.84Buy
PolyPid Ltd. stock logo
PYPD
PolyPid
7/21/2026Reiterated Rating$4.29$13.00Buy
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
7/20/2026Boost Price Target$19.07$24.00Buy
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
7/14/2026Reiterated Rating$1.17Buy
Omeros Corporation stock logo
OMER
Omeros
6/26/2026Lower Price Target$8.64$33.00Buy
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
6/25/2026Reiterated Rating$2.12$7.00Buy
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
6/23/2026Reiterated Rating$13.37$20.00Buy
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
6/23/2026Reiterated Rating$12.90$26.00Buy
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
6/22/2026Reiterated Rating$5.37$12.00Buy
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
6/18/2026Reiterated Rating$0.81$1.00Negative
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
6/18/2026Downgrade$0.80$1.00Hold
Omeros Corporation stock logo
OMER
Omeros
6/10/2026Reiterated Rating$9.97$40.00Buy
Talphera, Inc. stock logo
TLPH
Talphera
6/5/2026Initiated Coverage$0.80$3.00Buy
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
6/3/2026Lower Price Target$0.45$2.00Buy
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
6/1/2026Lower Price Target$1.11$8.00Buy
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
5/20/2026Reiterated Rating$2.20$10.00Buy
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
5/20/2026Reiterated Rating$1.59$8.00Buy
Omeros Corporation stock logo
OMER
Omeros
5/14/2026Reiterated Rating$14.38$40.00Buy
MannKind Corporation stock logo
MNKD
MannKind
5/7/2026Boost Price Target$3.56$10.00Buy
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
5/6/2026Reiterated Rating$14.66$21.00Buy
Trump’s Plan To Cheat History (Ad)

China has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely. Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years.tc pixel

Watch Porter Stansberry's full interview and see his top pick now
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
5/4/2026Reiterated Rating$7.55$11.00Buy
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
4/22/2026Reiterated Rating$7.02$11.00Buy
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
4/16/2026Reiterated Rating$3.55$12.00Buy
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
4/13/2026Initiated Coverage$2.68$10.00Buy
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
3/27/2026Reiterated Rating$1.08$11.00Buy
Journey Medical Corporation stock logo
DERM
Journey Medical
3/26/2026Reiterated Rating$6.83$13.00Buy
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
3/25/2026Reiterated Rating$2.90$12.00Buy
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3/20/2026Reiterated Rating$36.30$60.00Buy
Pelthos Therapeutics Inc. stock logo
PTHS
Pelthos Therapeutics
3/19/2026Reiterated Rating$22.44$60.00Buy
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
3/17/2026Lower Price Target$7.39$11.00Buy
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
3/11/2026Reiterated Rating$5.65$29.00Buy
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
3/9/2026Reiterated Rating$11.80$21.00Buy
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
3/2/2026Reiterated Rating$6.08$10.00Buy
MannKind Corporation stock logo
MNKD
MannKind
2/25/2026Reiterated Rating$3.54$11.00Buy
PolyPid Ltd. stock logo
PYPD
PolyPid
2/11/2026Reiterated Rating$4.59$13.00Buy
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2/10/2026Reiterated Rating$13.83$20.00Buy
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2/10/2026Reiterated Rating$1.09$9.00Buy
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
2/3/2026Reiterated Rating$6.23$29.00Buy
MannKind Corporation stock logo
MNKD
MannKind
1/26/2026Reiterated Rating$5.49$11.00Buy
CorMedix Inc stock logo
CRMD
CorMedix
1/23/2026Lower Price Target$7.44$13.00Buy
Indivior PLC stock logo
INDV
Indivior
1/12/2026Boost Price Target$35.44$48.00Buy
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
1/9/2026Reiterated Rating$48.78$60.00Buy
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
1/9/2026Reiterated Rating$13.44$20.00Buy
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
1/9/2026Reiterated Rating$11.21$21.00Buy
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
1/9/2026Reiterated Rating$1.39$11.00Buy
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
1/9/2026Reiterated Rating$8.59$12.00Buy
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
1/9/2026Reiterated Rating$8.13$10.00Buy
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
1/9/2026Reiterated Rating$1.50$6.00Buy
MannKind Corporation stock logo
MNKD
MannKind
1/8/2026Reiterated Rating$6.16Buy
Omeros Corporation stock logo
OMER
Omeros
1/8/2026Boost Price Target$14.09$40.00Buy
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
1/6/2026Reiterated Rating$2.06$8.00Buy
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
12/30/2025Set Price Target$8.82$26.00
Omeros Corporation stock logo
OMER
Omeros
12/24/2025Reiterated Rating$14.93Buy
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
12/15/2025Boost Price Target$2.55$8.00Buy
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
12/3/2025Initiated Coverage$2.16$8.00Buy
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
12/3/2025Initiated Coverage$2.11$8.00Buy
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
12/1/2025Reiterated Rating$0.89$9.00Buy
CorMedix Inc stock logo
CRMD
CorMedix
11/13/2025Boost Price Target$11.42$18.00Buy
MannKind Corporation stock logo
MNKD
MannKind
11/10/2025Reiterated Rating$5.44Buy
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
11/7/2025Reiterated Rating$7.44$10.00Buy
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
11/7/2025Boost Price Target$40.66$46.00Buy
Indivior PLC stock logo
INDV
Indivior
10/30/2025Boost Price Target$29.53$35.00Buy
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
10/21/2025Reiterated Rating$2.25$11.00Buy
Omeros Corporation stock logo
OMER
Omeros
10/15/2025Boost Price Target$10.20$20.00Buy
MannKind Corporation stock logo
MNKD
MannKind
10/13/2025Reiterated Rating$4.88$11.00Buy
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
9/24/2025Lower Price Target$3.65$7.00Buy
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
9/22/2025Initiated Coverage$1.21$10.00Buy
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
9/22/2025Initiated Coverage$1.18$10.00Buy
MannKind Corporation stock logo
MNKD
MannKind
9/18/2025Reiterated Rating$5.39$11.00Buy
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
9/17/2025Boost Price Target$96.81$121.00Buy
Do this before December or regret it (Ad)

Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.tc pixel

Watch Porter Stansberry's full briefing and get his three steps to prepare before December.
MannKind Corporation stock logo
MNKD
MannKind
9/2/2025Boost Price Target$5.72$11.00Buy
MannKind Corporation stock logo
MNKD
MannKind
8/25/2025Reiterated Rating$4.05$9.00Buy
Journey Medical Corporation stock logo
DERM
Journey Medical
8/25/2025Initiated Coverage$7.47$13.00Buy
Valneva SE Sponsored ADR stock logo
VALN
Valneva
8/25/2025Reiterated Rating$9.45$18.00Buy
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
8/21/2025Initiated Coverage$2.58$12.00Buy
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
8/20/2025Reiterated Rating$5.38$12.00Buy
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
8/19/2025Initiated Coverage$4.50$9.00Buy
Valneva SE Sponsored ADR stock logo
VALN
Valneva
8/19/2025Initiated Coverage$12.14$18.00Buy
PolyPid Ltd. stock logo
PYPD
PolyPid
8/13/2025Reiterated Rating$3.52$13.00Buy
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
8/13/2025Reiterated Rating$2.29$7.00Buy
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
8/12/2025Initiated Coverage$7.20$10.00Buy
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
8/11/2025Upgrade$34.93$44.00Strong-Buy
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
8/8/2025Reiterated Rating$81.49$93.00Buy
CorMedix Inc stock logo
CRMD
CorMedix
8/8/2025Lower Price Target$10.81$17.00Buy
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
8/7/2025Upgrade$9.17$29.00Buy
Indivior PLC stock logo
INDV
Indivior
8/6/2025Initiated Coverage$21.80$27.00Buy
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
7/28/2025Initiated Coverage$7.40$20.00Buy
MannKind Corporation stock logo
MNKD
MannKind
7/16/2025Upgrade$3.85$9.00Buy
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
7/10/2025Initiated Coverage$65.31$84.00Buy
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
7/2/2025Initiated Coverage$8.95$26.00Buy
CorMedix Inc stock logo
CRMD
CorMedix
6/30/2025Initiated Coverage$12.50$20.00Buy
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
6/26/2025Initiated Coverage$4.31$12.00Buy
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
6/12/2025Initiated Coverage$0.82$7.00Buy
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
6/9/2025Initiated Coverage$2.10$6.00Buy
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
6/5/2025Upgrade$1.65$5.00Buy
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
6/2/2025Initiated Coverage$1.25$9.00Buy
PolyPid Ltd. stock logo
PYPD
PolyPid
6/2/2025Upgrade$2.84$11.00Buy
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
5/28/2025Initiated Coverage$6.16$21.00Buy